Free Trial

Xeris Biopharma (XERS) News Today

Xeris Biopharma logo
$3.06 +0.05 (+1.66%)
(As of 11/20/2024 ET)
Piper Sandler Downgrades Xeris Biopharma (NASDAQ:XERS) to Neutral
Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.60
FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst
Xeris Biopharma downgraded to Neutral from Overweight at Piper Sandler
Xeris Biopharma price target raised to $6.60 from $6 at H.C. Wainwright
Xeris Biopharma Holdings, Inc. stock logo
FY2024 EPS Estimates for Xeris Biopharma Raised by Analyst
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst O. Livnat now forecast
Xeris Biopharma Holdings, Inc. stock logo
HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at HC Wainwright reduced their FY2027 earnings estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst O. Livnat now expects that t
Xeris Biopharma Holdings, Inc. stock logo
HC Wainwright Forecasts Strong Price Appreciation for Xeris Biopharma (NASDAQ:XERS) Stock
HC Wainwright upped their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a "buy" rating in a research report on Monday.
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Lowered to Neutral Rating by Piper Sandler
Piper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a research note on Monday.
Xeris Biopharma Reports Record Third Quarter Revenue
Xeris Pharmaceuticals (XERS) Gets a Buy from Craig-Hallum
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (XERS) to Release Quarterly Earnings on Friday
Xeris Biopharma (NASDAQ:XERS) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.
Oppenheimer Remains a Buy on Xeris Pharmaceuticals (XERS)
Xeris Biopharma: Time For A Reassessment
Xeris Biopharma Holdings, Inc. stock logo
XTX Topco Ltd Sells 223,267 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
XTX Topco Ltd lessened its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 31,782 shares of the company's stock after selling 223,267 shares during the period. XTX Topco
Xeris Biopharma Holdings, Inc. stock logo
Renaissance Technologies LLC Acquires 342,300 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 33.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,351,640 sh
3 Penny Stocks to Buy With $500
XERS Jan 2025 5.000 call
Xeris to Participate in Upcoming Investor Conferences
XERS Sep 2024 5.000 put (XERS240920P00005000)
Xeris Biopharma Holdings, Inc. stock logo
Brokers Offer Predictions for Xeris Biopharma Holdings, Inc.'s Q3 2024 Earnings (NASDAQ:XERS)
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2024 earnings estimates for shares of Xeris Biopharma in a research note issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now expects that the company will earn ($0.10) p
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) to Post FY2027 Earnings of $0.27 Per Share, HC Wainwright Forecasts
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 EPS estimates for Xeris Biopharma in a report issued on Wednesday, August 14th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $0.27
Xeris Biopharma Holdings, Inc. stock logo
Vanguard Group Inc. Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Vanguard Group Inc. grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 7.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,606,242 shares of the company's stock after acquiring an additi
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Buys $10,155.45 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John P. Schmid acquired 4,285 shares of Xeris Biopharma stock in a transaction on Friday, August 9th. The stock was acquired at an average price of $2.37 per share, with a total value of $10,155.45. Following the purchase, the director now directly owns 20,685 shares in the company, valued at $49,023.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Xeris Biopharma (NASDAQ:XERS - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 37.58%. The company had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same period last year, the business earned ($0.14) EPS.
Craig-Hallum Keeps Their Buy Rating on Xeris Pharmaceuticals (XERS)
XERS Aug 2024 2.000 put (XERS240816P00002000)
Xeris Biopharma Holdings, Inc. stock logo
Leerink Partnrs Comments on Xeris Biopharma Holdings, Inc.'s Q2 2024 Earnings (NASDAQ:XERS)
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Leerink Partnrs boosted their Q2 2024 earnings per share estimates for Xeris Biopharma in a note issued to investors on Tuesday, July 9th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.11) per share for the
Xeris Biopharma Holdings, Inc. stock logo
Invenomic Capital Management LP Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Invenomic Capital Management LP bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 568,619 shares of the company's stock, valued at approxi
Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

XERS Media Mentions By Week

XERS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

XERS
News Sentiment

0.12

0.46

Average
Medical
News Sentiment

XERS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

XERS Articles
This Week

4

2

XERS Articles
Average Week

Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:XERS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners